Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tekmira Pharmaceuticals Corporation (TKMR): Falcon Edge Capital Discloses 10% Passive Stake

Page 1 of 2

Another one of the funds we track here at Insider Monkey has made a big move into Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), as it was revealed in a filing that Richard Gerson and Navroz D. Udwadia’s Falcon Edge Capital has disclosed a 9.9% stake in the biotech company, reporting ownership of 2.22 million shares.

Navroz Udwadia - Falcon Edge Capital

Falcon Edge Capital utilizes a long/short equity strategy, and invests in markets around the globe, with an emphasis on emerging markets. It was founded in 2012 by Gerson, who was a founding member of Blue Ridge Capital. As of September 30, 2014, the fund’s equity portfolio was valued at $1.55 billion. Their most valuable holdings included Spirit Aerosystems Holdings, Inc. (NYSE:SPR) with 3.35 million shares, Actavis plc (NYSE:ACT) (formerly Watson Pharmaceuticals) with 429,167 shares, and 480 shares of Warren Buffett’s Berkshire Hathaway Inc (BRK.A), which were valued at $206,900 each as of September 30, making Falcon Edge’s mere 480 shares worth over $93 million.

The disclosure by Falcon Edge of 2.22 million shares in Tekmira is remarkably similar to the disclosure of 2.21 million shares purchased by Peter Kolchinsky’s RA Capital Management, as we reported on just days ago. Both disclosures represented new positions in the company, and gave each hedge fund a 9.9% stake, though Falcon Edge owns 85,200 more shares. Both positions were also dated to January 12, the same day Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) announced a merger with OnCore Biopharma, with OnCore becoming a wholly-owned subsidiary of Tekmira.

Page 1 of 2
Loading...